	Response to "Calendar-time bias in a TriNetX study of GLP-1 receptor agonists, SGLT2 inhibitors and bladder cancer survival". Urol Oncol Kohler J, Rodler S. PMID: 42869700 [PubMed - as supplied by publisher]
	Transitioning from template-based groin dissection to dynamic sentinel node biopsy in penile cancer: Prospective validation of a standardization step. Urol Oncol Prakash G, Shaikh S, Arora A, Pal M, Misra A, Gujela A, Bakshi G, Rangarajan V, Agrawal A, Menon S. PMID: 42869699 [PubMed - as supplied by publisher]
	Initial complete local therapy without systemic therapy versus systemic-therapy-based management in selected patients with oligometastatic renal cell carcinoma: a matched comparative study. Radiother Oncol Kim HU, Lee HI, Park I, Kim JK, Kim YJ. PMID: 42869248 [PubMed - as supplied by publisher]
	Immune Checkpoint Inhibitors in Metastatic Renal Cell Carcinoma With Sarcomatoid Dedifferentiation: A Multicenter Retrospective Study. J Natl Compr Canc Netw Gopalakrishnan D, Fujiwara Y, Collier KA, Park JJ, Zaemes JP, Lam ET, Alaklabi S, Jaeger EB, Barata PC, Kauffman EC, Atkins MB, Alva A, Yang Y, George S. PMID: 42869085 [PubMed - as supplied by publisher]
	[Molecular-Based Diagnostics and Therapy of Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)]. Aktuelle Urol Kesch C, Hadaschik B, von Amsberg G. PMID: 42869040 [PubMed - as supplied by publisher]
	Adenoma laterality and risk of subsequent colorectal cancer: Secondary analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer trial. Surgery Frebault J, Troester A, Huo L, Rudser K, Hassan I, Shaukat A, Goffredo P. PMID: 42868921 [PubMed - as supplied by publisher]
	Real-World Tumor-Informed Circulating Tumor DNA Dynamics and Survival Associations in Advanced Urothelial Cancer Treated With First-Line Enfortumab Vedotin and Pembrolizumab. JCO Precis Oncol Nimgaonkar V, Arbuiso A, Vlachou E, Johnson BA, Smith A, Kates M, Patel S, Singla N, Russell S, Rourke K, Elias R, Matoso A, Baraban EG, Hahn NM, Hoffman-Censits J. PMID: 42868336 [PubMed - indexed for MEDLINE]
	Fracture and Vertebral Augmentation Utilization Following Androgen Deprivation Therapy in Men With Prostate Cancer: A Propensity Score-matched Cohort Study. Global Spine J Taka T, Cummings C, Meng S, Miner A, Dietrich G, Shin D, Trivedi T, Goodwin R, Richardson W, Danisa O. PMID: 42868235 [PubMed - as supplied by publisher]
	Lower Urinary Tract Complications After Radiotherapy for Prostate Cancer: An Organ-Based Clinical Framework. Int Braz J Urol Gomes CM, do Nascimento LAP, Ockrim J, Laferreira LS, Nobrega R, Pace K, Loufopoulos I, Greenwell T. PMID: 42868174 [PubMed - indexed for MEDLINE]
	Joint Associations of Abdominal Obesity, General Obesity, and Smoking with Bladder Cancer Risk Among Postmenopausal Women: A Nationwide Cohort Study. Cancer Epidemiol Biomarkers Prev Han M, Park JH, Hong JY, Han K, Shen JJ. PMID: 42867947 [PubMed - as supplied by publisher]
	Opioid-free versus opioid-based anesthesia for robot-assisted radical prostatectomy: a single-center randomized controlled trial. J Robot Surg Sk, , Cicio M, Kowal T, Kwinta A, Bugielska R, Szpunar W, Szpor J, Maciejewska K, , Lonc T, Drygalski T, Maciejewski P. PMID: 42867736 [PubMed - indexed for MEDLINE]
	Artificial Intelligence for Prostate Cancer Detection and Screening on MRI in Global Populations: The SCARLET-1 Study. Radiology Saha A, Bosma JS, Twilt JJ, Ng ABCD, Asif A, Magudia K, Larson PEZ, Xie Q, Zhang X, Minh CP, Gitau SN, Schoots IG, Boomsma MF, Cuocolo R, Papanikolaou N, Regge D, Patel HD, Yakar D, Elschot M, Veltman J, Turkbey B, Obuchowski NA, Fütterer JJ, Padhani AR, Mayor N, Ahmed HU, Jäderling F, Nordström T, Eklund M, Kasivisvanathan V, de Rooij M, Huisman H, PI-CAI, PI-CAI. PMID: 42867371 [PubMed - indexed for MEDLINE]
	Urinary Extracellular Vesicle-Associated EphA2 Predicts Intravesical Recurrence in Bladder Cancer. Int J Urol Hashimoto M, Tomiyama E, Inoki L, Miki K, Nakayama T, Fujimoto S, Toyoda S, Kikuchi T, Ukekawa R, Yamamoto Y, Minami T, Yoshimura K, Nonomura N, Fujita K. PMID: 42866931 [PubMed - indexed for MEDLINE]
	Complementary Diagnostic Value of ZEB1 and CK7 in Renal Oncocytoma and Chromophobe Renal Cell Carcinoma. Appl Immunohistochem Mol Morphol Filipovi, Soldatovi, , Dun, Jevti, Nikoli, Vukajlovi, Radojevi. PMID: 42866914 [PubMed - as supplied by publisher]
	Filling the information gap: a validated comparison of ChatGPT, Gemini, and Claude for penile cancer patient education. Transl Androl Urol Yang J, Bushati Y, Lorger S, Saad J, Rathore P. PMID: 42866825 [PubMed]
	Comparative outcomes of radical prostatectomy, radiotherapy, and radiotherapy plus androgen deprivation therapy for high-risk and very high-risk prostate cancer: a narrative review. Transl Androl Urol Tun KH, Xiong X, Xu H, Yang L. PMID: 42866815 [PubMed]
	Enhancing intravesical bladder cancer therapy: from mucoadhesive to targeted drug delivery strategies. Front Med (Lausanne) Sahini H, Anzengruber M, Lächelt U. PMID: 42865741 [PubMed]
	Neoadjuvant disitamab vedotin (RC-48) plus a PD-1 inhibitor in muscle-invasive bladder cancer: a multicenter real-world study with stratification by HER2 expression and tertiary lymphoid structures. Front Immunol Rao XP, Zou XC, Liu X, Xu LY, Huang JB, Yuan YY, Chen T, Zeng T. PMID: 42865476 [PubMed - indexed for MEDLINE]
	Clinical Markers of Vulnerability for Bleeding in Men WithÂ Prostate Cancer and Antithrombotic Treatment. Cancer Rep (Hoboken) Björkhem-Bergman L, Hedman C, Szilcz M, Frisk G. PMID: 42865304 [PubMed - indexed for MEDLINE]
	Impact of Prior Holmium Laser Enucleation of the Prostate on Outcomes After Robot-Assisted Radical Prostatectomy. Int J Urol Nishino T, Shimbo M, Oguchi T, Sano M, Narimoto K, Hattori K, Endo F. PMID: 42865148 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 182147

Page 1 of 9108



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy